docetaxel accord
accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w
forteo
eli lilly australia pty ltd - teriparatide -
decapeptyl cr for injection 3.75 mgsyringe
ferring pharmaceuticals private limited - triptorelin acetate 4.12 mg/syringe eqv triptorelin - injection, powder, for solution - 3.75 mg/syringe - triptorelin acetate 4.12 mg/syringe eqv triptorelin 3.75 mg/syringe
flazon suppositories vaginal
medical horizon ltd - metronidazole - suppositories vaginal - 500mg
mytolac lanreotide (as acetate) 60 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac lanreotide (as acetate) 120 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 133.33 mg (equivalent: lanreotide, qty 120 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac lanreotide (as acetate) 90 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 100 mg (equivalent: lanreotide, qty 90 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
ortho organizers orthodontic system
a2z dental & medical supplies pte. ltd. - dental - it is intended for the correction of orthodontic malocclusions as diagnosed by dentist or orthodontist. the device is used to transmit and provide axial directional control to the kinetic energy from an orthodontic archwire, for movement of individual teeth.
yarina plus 3mg+30mcg+451mcg tablets film-coated
bayer weimar gmbh & co. kg - drospirenone, ethinylestradiol, levomefolate calcium - tablets film-coated - 3mg+30mcg+451mcg
zocardis 30 tablets film-coated
a.menarini manufacturing logistics and services s.r.l. - zofenopril (zofenopril calcium) - tablets film-coated - 30mg